Multi-engager antibody complex TAB-16/15 for enhanced NK cell function
TAB-16/15 is a novel antibody complex designed to augment the function of natural killer (NK) cells by engaging CD16, blocking ADAM17, and containing IL-15. This complex enhances NK cell activation and proliferation, improving their anti-tumor activity.
Overview
TAB-16/15 is an innovative multi-engager antibody complex developed to enhance the effector functions of natural killer (NK) cells. By simultaneously engaging CD16, blocking ADAM17, and incorporating IL-15, TAB-16/15 aims to significantly improve NK cell activation, proliferation, and function. The technology is particularly promising for modulating the tumor microenvironment and boosting the body's immune response against heterogeneous tumor cells, especially in ovarian cancer.
Technical specifications
Key features:
- CD16 Engagement: Promotes NK cell activation and enhances their cytotoxic activity.
- ADAM17 Blockage: Prevents the cleavage of activating receptors on NK cells, maintaining their functionality.
- IL-15 Incorporation: Supports NK cell priming and survival, further enhancing their anti-tumor capabilities.
- Modular Design: Allows for customization with additional antibody engagers to expand functionality.
Technology readiness level
TAB-16/15 is currently at TRL 4, indicating that it has been validated in a laboratory environment. The next steps involve scaling up the complex and evaluating its effects on NK cell activation, proliferation, and control of ovarian cancer through both in vitro and in vivo studies.
About University of Minnesota
The University of Minnesota is a flagship, comprehensive public research university spanning multiple campuses, with a large research enterprise and clinical integration. Industry engages through co-located labs on the Twin Cities campuses, access to an academic health system for clinical translation, and pilot and field-testing facilities that speed scale-up. A statewide extension network and outreach centers provide real-world sites and data partnerships across Minnesota, while proximity to a dense medtech and Fortune 500 corridor enables frequent collaboration. Research is supported by competitive federal funding, including NIH, NSF, DOE, USDA, and DoD. A dedicated technology transfer office manages IP, licensing, sponsored research agreements, and startup incubation to speed commercialization.
delivered to your inbox.